U.S. Supreme Court snubs Novartis appeal over arthritis drug Enbrel
By Syndicated Content By Andrew Chung (Reuters) â The U.S. Supreme Court on Monday dashed Novartis AGâs hopes of launching a generic version of Amgen Incâs multibillion-dollar rheumatoid arthritis Enbrel, declining to hear the companyâs challenge to two patents on the drug. The justices turned away Novartis subsidiary Sandoz Incâs appeal of a lower court decision that upheld the validity of the patents. Enbrel, a biologic also known as etanercept used to treat adults with moderate to severe active rheumatoid arthritis, is Amgenâs top-selling drug, acc...
Source: wsau.com